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Abstract
Dysregulation of c-FLIP (cellular FADD-like IL-1β-converting enzyme inhibitory protein) has 
been shown in several diseases including cancer, Alzheimer’s disease, and chronic obstructive 
pulmonary disease (COPD). c-FLIP is a critical anti-cell death protein often overexpressed in 
tumors and hematological malignancies and its increased expression is often associated with a 
poor prognosis. c-FLIP frequently exists as long (c-FLIPL) and short (c-FLIPS) isoforms, regulates 
its anti-cell death functions through binding to FADD (FAS associated death domain protein), an 
adaptor protein known to activate caspases-8 and -10 and links c-FLIP to several cell death 
regulating complexes including the death-inducing signaling complex (DISC) formed by various 
death receptors. c-FLIP also plays a critical role in necroptosis and autophagy. Furthermore, c-
FLIP is able to activate several pathways involved in cytoprotection, proliferation, and survival of 
cancer cells through various critical signaling proteins. Additionally, c-FLIP can inhibit cell death 
induced by several chemotherapeutics, anti-cancer small molecule inhibitors, and ionizing 
radiation. Moreover, c-FLIP plays major roles in aiding the survival of immunosuppressive tumor-
promoting immune cells and functions in inflammation, Alzheimer’s disease (AD), and chronic 
obstructive pulmonary disease (COPD). Therefore, c-FLIP can serve as a versatile biomarker for 
cancer prognosis, a diagnostic marker for several diseases, and an effective therapeutic target. In 
this article, we review the functions of c-FLIP as an anti-apoptotic protein and negative prognostic 
factor in human cancers, and its roles in resistance to anticancer drugs, necroptosis and autophagy, 
immunosuppression, Alzheimer’s disease, and COPD.
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Introduction
c-FLIP or CLARP (caspase-like apoptosis-regulatory protein) plays important roles in 
apoptosis, necroptotic cell death [1–4], and autophagy [1]. It also triggers resistance to 
anticancer agents and cytokines [1,5–10], as well as immune suppression [1,9]. Furthermore, 
recent results show that c-FLIP plays important roles in other diseases [11–13]. Therefore, c-
FLIP is a valuable biomarker of prognosis and a reliable molecular target for developing 
therapeutics for cancer [1,9,14,15]. AD, and immune-related diseases. This review 
concentrates on the usefulness of c-FLIP as a biomarker. We discuss how c-FLIP prevents 
apoptosis and induces cytokine and chemotherapy drug resistance in cancer cells, its role for 
cancer prognosis, necrosis and autophagy, and its involvement as a marker of AD and 
COPD.
Literature Review
Apoptosis signaling pathways and role of c-FLIP
Three major signaling pathways, the intrinsic or mitochondrial pathway, the extrinsic or cell 
surface death receptors (DRs) pathway, and the endoplasmic reticulum (ER) stress-induced 
apoptosis pathway are known to regulate apoptosis (Figures 1 and 2) [1,4]. In the 
mitochondrial apoptotic pathway, anti- and pro-apoptotic members of the Bcl-2 family 
cooperate and regulate the release of cytochrome c and other apoptosis-inducing factors 
from the mitochondria to the cytosol [16,17]. Cytochrome c and dATP bind to apoptotic 
proteinase-activating factor-1 (Apaf-1) and make a complex with adenine nucleotides to 
form the apoptosome, which promotes procaspase-9 autoactivation [17,18]. Formation of 
apoptosome is important in the mitochondrial apoptosis pathway and by binding to 
cytochrome c it activates the initiator caspase-9. This caspase in turn activates caspases-2, 
-3, -6, -7, -8, and -10 [17–22]. Successful apoptosis requires direct activation of the pro-
apoptotic proteins Bax and Bak at the mitochondria by a member of the pro-apoptotic family 
of proteins including Bid, Bim, or PUMA [20]. Cytochrome c, release and opening the 
permeability transition pore (PTP), and a collapse of mitochondrial transmembrane potential 
(Δψm) are associated processes and are due to the intake of endoplasmic reticulum (ER) 
Ca2+ release [20–22] into cytosol.
In the death receptor (DR)-mediated or extrinsic apoptosis pathway, Fas/Fas Ligand (FasL) 
[CD95/CD95 Ligand, CD95L] interaction, TRAIL/DR4 or TRAIL/DR5 interaction, or the 
binding of tumor necrosis factor α (TNF-α) with its receptor, TNF receptor 1 (TNFR1), 
initiates apoptosis (Figures 1 and 2). Similarly, binding of the agonistic antibodies to these 
respective receptors also initiates the apoptotic signaling cascade. Following the interactions 
of the DR ligands or DR agonistic antibodies with their respective trimerized DRs, the 
adaptor molecule Fas-Associated Death Domain (FADD) is recruited to the DRs via death 
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domain (DD) interactions, whereas procaspase-8, procaspase-10, and c-FLIP are recruited to 
the death-inducing signaling complex (DISC) via death effector domain (DED) interactions 
[23,24]. Therefore, the DISC consists of trimerized DRs, FADD, procaspase-8/-10, and c-
FLIP. Procaspase-8 and procaspase-10 form a complex with FADD and are autocatalytically 
activated to form the active initiator caspase-8 or caspase-10.
Caspase-8 also becomes activated intrinsically, and not extrinsically, as a result of c-Myc 
inducing the down-regulation of c-FLIPL. Therefore, c-FLIPL may be of importance not 
only in regulating the death receptor ligand-induced apoptosis, but also in apoptotic 
processes triggered from within the cell [25]. Moreover, chromatin immunoprecipitation 
(ChIP) and luciferase assays identified the binding of c-Myc to the c-FLIPL promoter [26]. 
Moreover, after treating I/R rats with the c-Myc inhibitor 10058-F4, a significant decrease in 
c-FLIPL and an increase in cleaved caspases-8 and 3 was seen, providing further support for 
the functional role of c-FLIPL in intrinsic apoptosis [26].
Silencing c-FLIP caused sensitivity of tumor cells to death ligands and chemotherapeutic 
agents in cancer cell models [6,27]. Furthermore, in addition to its function as an anti-
apoptotic protein, c-FLIP has other functions such as increased cell proliferation and 
tumorigenesis [3,27]. In TNF-α-triggered apoptosis (Figure 2), TNFR1 internalizes and 
induces formation of Complex II containing RIP, TRADD, FADD, and caspase-8. Caspase-8 
autoactivation triggers activation of caspases-3 and -7, leading to apoptosis, and c-FLIP 
inhibits capsase-8 and -10 activation and apoptosis [3,28]. A pro-apoptotic Bcl-2 family 
member, Bid, is cleaved to the truncated Bid (tBid) by caspase-8 and -10 and triggers 
mitochondrial cytochrome c release. Thus, tBid links the death receptor pathway to 
mitochondrial pathway. After activation, both caspases-8 and -9 activate caspase- 3 and 
other caspases, and ultimately apoptosis. Mitochondria play a leading role in cellular 
respiration and homeostasis in the cells and transfer various signals for cell survival and 
death to the cytosol.
Ranjan and Pathak [29] demonstrated that c-FLIPL and FADD expression participate in 
balancing redox potential by regulating antioxidant levels. Further, they noticed that 
knockdown of c-FLIPL and induced expression of FADD results in rapid accumulation of 
intracellular ROS accompanied by JNK1 activation to enhance apoptosis. Therefore, besides 
their death receptor signaling, c-FLIPL and FADD play important roles in preventing 
mitochondrial mediated apoptosis. The interaction of the TNF-α trimer to TNF receptor 1 
(TNFR1) also triggers TNFR1 trimerization and Complex I formation participating in 
inducing the antiapoptotic proteins (Figure 2). Complex I contains TNFR1, TRADD, 
TRAF2, and RIP and is able to activate the NF-κB signaling pathway through the MEKK3-
IKK-IκB-NF-κB cascade and subsequently activates the transcription and expression of 
several genes including antiapoptotic factors such as IAPs, Bcl-2, and c-FLIP [3,30]. As 
shown in Figure 2, TNF-α treatment through Complex I can also cause activation of JNK 
and ERK through the MAPK signaling pathway. The ubiquitin#specific proteases system 2 
(USP2) stabilizes the ubiquitin-E3-ligase ITCH and lowers NF-κB basal activity, which 
leads to reduced c-FLIP mRNA production; proteasomal degradation of c- FLIP isoforms is 
also elevated by its negative regulator proteasome ITCH [31]. Therefore, levels of c-FLIP 
protein isoforms decrease and apoptosis increases. The TRAIL receptors, DR4 or DR5, can 
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also promote alternative signaling pathways such as JNK, MAPK, or NF-κB by recruiting 
RIP1 and TRAF2 or TRAF5 to form a secondary signaling complex [32,33]. Activation of 
NF-κB in this pathway also results in increased expression of c-FLIP (Figure 2). Studies 
with TRADD-deficient mouse embryo fibroblasts (MEFs) have documented that RIP1 is 
also recruited to the TRAIL receptor by interacting with TRADD, and both RIP1 and 
TRADD protect against TRAIL-induced apoptosis [5,34]. In these TRADD-deficient MEFs, 
MAPK and NF-κB pathway activation was impaired, confirming the role of TRADD as the 
key adaptor protein mediating nonapoptotic signaling by DRs [5,34]. Indeed, the human T-
cell leukemia virus type 1 (HTLV-1) Tax protein triggers c- FLIP production through 
activation of the IKK-NF-κB cascade the via DR4/DR5 pathway [35].
It is also known that TNF-α and Fas trigger the cleavage of mitogen-activated protein 
kinase/ERK kinase kinase (MEKK), resulting in production of a constitutive active form of 
MEKK1 and leading to JNK activation in c-FLIP knockdown cells [36]. In the absence of 
caspase-8 activity, the death receptors promote death by programmed necrosis (necroptosis) 
which requires the kinases receptor-interacting kinase 1 (RIPK1), RIPK3, and mixed-lineage 
kinase-like protein (MLKL) [37].
The endoplasmic reticulum (ER) stress-induced apoptosis pathway is the result of internal 
cellular stress like the accumulation of damaged glycoproteins [38], or exogenous stress, 
such as chemotherapeutic agents and hypoxia [39], which activate the process of cellular 
responses to stress, termed the unfolded protein response (UPR) [40]. UPR plays a major 
role in the homeostasis of ER. Prolonged or excessive ER stress triggers signaling pathways 
resulting in cell death. Triggering apoptosis via ER stress is usually associated with 
increased expression of DR5, downregulation of c-FLIP, caspase activation, and 
participation of the JNK pathway. ER and mitochondria cross-talk through forming 
mitochondria-ER associated membranes (MAMs) or mitochondria associated ER 
membranes (MERCs) [41] that reciprocally transmit signals under stress conditions, 
triggering synergistic death responses [42].
c-FLIP spliced variants and the structure of c-FLIP isoforms
The mammalian cellular homolog of viral FLICE-inhibitory proteins (v-FLIPS) was termed 
c-FLIP [43]. While c-FLIP consists of a family of alternatively spliced variants, three of 
these variants including the 26 kDa short form (c-FLIPS), the 55 kDa long form (c-FLIPL) 
and the 24 kDa form (c- FLIPR) are expressed as proteins (Figure 3) [20,44]. c-FLIPR is 
smaller than c-FLIPS and has a similar pattern of expression as c-FLIPS during activation of 
primary human T cells and is strongly induced in T cells upon CD3/CD28 co-stimulation 
[45]. In humans, three isoforms of c-FLIP, c- FLIPL (55 kDa), c-FLIPS (27 kDa), and c-
FLIPR (25 kDa) have been identified [1,46]. These isoforms contain two DEDs (Figure 3). 
c-FLIPL also contains a catalytically inactive caspase-like [44] domains (p20 and p12). 
Moreover, c-FLIPS has an additional isoform-specific 19 amino acids in its C-terminal 
domain. Moreover, c-FLIPL has a caspase-8 cleavage site at position Asp-376 (LEVD) and 
cleavage at this site results in generation of the fragment variant p43c-FLIP, p43- FLIP, and 
p22-FLIP [1,47]. The C-terminal region of c-FLIPS and c-FLIPR plays an important role in 
ubiquitination and degradation and their anti-apoptotic function.
Safa et al. Page 4





















c-FLIP activates cytoprotective and proliferation pathways
As we previously discussed [1] several pathways with major roles in regulating cell survival, 
proliferation, and carcinogenesis can be activated by c-FLIP (Figure 2) [47–55]. DNA-
PK/Akt pathway also can regulate the expression of c-FLIP [56]. Furthermore, interaction of 
c-FLIPL with MKK7 might selectively suppress JNK activation [57]. c-FLIP may also 
regulate pathways participating in the production of inflammatory cytokines, tumor cell 
migration and metastasis [58,59], alter cell cycle progression and enhance cell proliferation 
and carcinogenesis [1,9]. Furthermore, overexpression of c-FLIP can alter cell cycle 
progression and enhance cell proliferation and carcinogenesis [1,9].
c-FLIP as a an anti-apoptotic protein
It has been shown that c-FLIP inhibits death receptor-mediated apoptosis as well as 
apoptosis induced by a variety of cancer chemotherapeutic agents and small molecule 
targeted anticancer compounds and ionizing radiation [1,51]. Additionally, major roles for c-
FLIP in promoting the survival of immunosuppressive tumor-promoting immune cells have 
been discovered [9]. Thus, c-FLIP is a rational anticancer therapeutic target. c-FLIPL 
modulates signals [11] leading to both cell death and cell growth [60]. c-FLIPL is 
upregulated in human tumors [51,61], rendering tumor cells resistant to therapies and 
immune surveillance [62], Regulatory T cells or Tregs turn off immune responses and have 
been used for immunotherapies. Treg cells compared to conventional T cells are more 
susceptible to apoptosis due to low c-FLIP expression [63]. Treg-specific deletion of c-FLIP 
in mice has been shown to cause fatal autoimmune disease [29]. Therefore, c-FLIP function 
is essential for cell homeostasis and prevention of autoimmunity in Treg [63]. Given the fact 
that Treg cells control autoimmunity and inhibit anti-cancer immunity, c-FLIP could be used 
as a therapeutic target to modulate Treg cell abundance and immune responses in cancer or 
autoimmune disease [63].
c-FLIP has been shown to affect immune regulatory pathways enriched in NF-κB response 
to TNF, cytokine network, and genes upregulated by IL-6 via STAT3 [64]. This specific gene 
upregulation may be partially linked to NF-κB activation induced by the nuclear 
translocation of c-FLIP [64]. These authors uncovered a critically important dual role of c-
FLIP in myeloid cells. In mature monocytes, cancer-induced c-FLIP expression promoted 
immune suppressive functions and increased survival. On the other hand, constitutive c-FLIP 
activation in the myeloid lineage induced chronic inflammation associated with 
myeloproliferation and immune suppression. These results revealed that c-FLIP emerged as 
a novel factor for controlling cancer-associated chronic inflammation and immune 
dysfunction.
Role of c-FLIP in programmed necroptosis
Necroptosis is physiologically regulated by specific proteins including RIPK1, receptor 
interacting protein kinase 3 (RIPK3, also known as RIP3), and mixed lineage kinase-like 
protein (MLKL) [1]. Receptor interacting protein kinase 1 (RIPK1), also known as RIP1, is 
a protein which interacts with the TNF-α receptor 1 signaling complex and recent advances 
have shown the critical roles of RIPK1 in cell survival, apoptosis, and necroptosis [65,66]. 
Necroptosis is induced as a result of inhibiting caspase-8 activation regulated by the death 
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platform complex, Ripoptosome, and c-FLIP isoforms can switch apoptotic and necroptotic 
cell death. Moreover, the cellular inhibitor of apoptosis proteins (clAPs) blocks Ripotosome 
formation [1]. Interestingly, while c-FLIPL is able to prevent Ripoptosome formation, c-
FLIPS promotes its formation [1]. Therefore, these c-FLIP isoforms in the Ripoptosome 
determine whether cell death occurs by RIP3-dependent necroptosis or caspase-dependent 
apoptosis [1,67,68]. Molecularly, RIPK1 phosphorylates and activates RIPK3, and activated 
RIPK3 then phosphorylates MLKL. Subsequently, the phosphorylated MLKL oligomer 
form translocates to the plasma membrane and induces necrotic cell death by forming pores 
on the plasma membrane [69].
Autophagy and c-FLIP
In addition to inhibiting apoptosis, c-FLIPL can affect autophagy by (1) direct action on 
autophagy by competing with Atg3 binding to LC3, reducing LC3 processing and inhibiting 
autophagosome formation [1,70,71] and (2) by interacting with procaspase-10, it forms an 
enzymatic complex that can cleave the Bcl-2 associated transcription factor 1 (BCLAF1), 
which is an autophagy inducer. This cleaved BCLAF1 form displaces Bcl-2 from an 
inhibitory complex with Beclin-1 and Beclin-l-induced autophagy [71]. Disrupting or 
preventing formation of the procaspase-10/c-FLIPL complex may induce autophagic cell 
death [71]. Recently, it was shown that inhibition of c-FLIP overcomes acquired resistance 
to sorafenib by reducing endoplasmic reticulum stress (ERS)-related autophagy in 
hepatocellular carcinoma (HCC) [72].
c-FLIP as a valuable prognostic biomarker in various cancers
c-FLIP variants (c-FLIPL and c-FLIPS) serve as prognostic biomarkers for various cancer 
types. As shown in Figure 3, c-FLIPL has a bipartite nuclear localization signal (NLS) and a 
nuclear export signal (NES) in its C-terminal region, required for its transport between the 
nucleus [10] and the cytosol [73,74]. High expression of c-FLIP is lethal in human cancers 
including ovarian, colon, cervical, glioblastoma, breast, colorectal, and prostate cancers, and 
multiple myeloma [1,50,51,61,75,76]. Collectively, c-FLIP expression is frequently 
upregulated in various malignancies and correlates with poor prognoses. 
Immunohistochemical analysis has shown two distinct pools of c-FLIPL, which correlate the 
expression and the subcellular localization of c-FLIPL protein with patient therapeutic and 
survival outcomes [75,76]. Humphreys et al. [9] in a cohort of 184 non-small lung cancer 
(NSCLC) patients demonstrated high cytoplasmic but not nuclear c-FLIP significantly 
correlated with decreased overall survival. Valnet-Rabier et al. [77] showed that in 32 
Burkitt’s lymphoma cases, a mainly cytoplasmic pool of c-FLIP was highly correlated with 
poor patient outcome [77]. Several studies have identified c-FLIP as an independent adverse 
indicator in cancer and found both c-FLIPL and c-FLIPS play important roles in cancer 
patient treatment outcomes and that the expression of particular c-FLIP isoforms has 
prognostic clinical value [66,78–86]. Ullenhag et al. [87] showed in colorectal (CLR) cancer 
patients that c-FLIPL is an independent marker of poor prognosis. Furthermore, a high c-
FLIP level was shown to be an independent adverse prognostic marker in stage II and III 
CLR cancer and might identify patients with a high possibility of relapse [78]. Moreover, c-
FLIPL mRNA significantly correlates with poorer overall survival of a cohort of acute 
myeloid leukemia (AML) patients [88]. Zang et al. [89] using immunohistochemistry found 
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c-FLIP protein expression in IA2-IIIA cervical-squamous cell carcinoma patients and 
showed that high c-FLIP level was an independent negative indicator for disease-free 
survival (p=0.015). Lee et al. [90] found that c-FLIPL expression in invasive breast 
carcinomas with c-FLIPL-positive patients showed a poor prognosis (p<0.01). Furthermore, 
expression of c-FLIPL, lymph nodes status, and molecular subtypes were independent 
prognostic factors for these patients (p<0.05). McCourt et al. [91] have reported that 
expression levels of c-FLIP and heat shock protein 27 (HSP27) in prostate cancer correlated 
with the Gleason score sum and pathologic stage. A prostate cancer Gleason score or grade 
assists in determining how aggressively the tumor is likely to behave. The score helps to 
classify the cancer by grading how quickly it is likely to grow and is an indicator of how 
likely it is to metastasize outside the prostate gland. Elevated expression of c-FLIP was 
shown to antagonize the therapeutic response to androgen receptor targeted therapy in 
castration-resistant prostate cancer (CRPC) [92]. Furthermore, the overexpression of stromal 
c-FLIP promotes androgen-dependent prostate cancer growth and invasion [93]. Another 
significant role of c-FLIP is in the carcinogenesis and aggressiveness of endometrial 
carcinoma and might be a critical prognostic factor in this cancer [94]. Acute human 
papillomavirus (HPV) infection causes cervical intraepithelial neoplasia marked by high 
copy episomal viral DNA and L1/L2 capsid protein expression in the cells that facilitate 
sexual viral transmission. Recently, Nuovo et al. [14] showed that an increased level of c-
FLIP and elevated expression of importin-β, exportin-5, Mcl1, p16, and Ki67 are new 
biomarkers of human papillomavirus infection in acute cervical intraepithelial neoplasia.
Identification of reliable biomarkers remains a crucial factor to evaluate clinical progress in 
pancreatic ductal adenocarcinoma (PDAC), a lethal cancer. Haag et al. [94] found that c-
FLIP overexpression in pancreatic intraepithelial neoplasia (PanIN) lesions (the most 
prevalent type of early lesion, arising from the ductal epithelial cells leading to moderate 
dysplasia, high-grade dysplasia, and invasive carcinoma), and PDAC, compared to normal 
pancreatic ducts. In addition, knockdown of c-FLIP increased death receptor-triggered 
apoptosis in PDAC cell lines. Schmid et al. [95] demonstrated that c-FLIP expression status 
is a [32] valuable prognostic biomarker in PDAC. Subsequently, these investigators explored 
the prognostic significance of c- FLIP protein expression in PDAC in a well-defined cohort 
including clinical parameters, and other PDAC cohorts. Interestingly, the complete lack of c-
FLIP was associated with a highly aggressive clinical course [94]. c-FLIPL is usually 
considered to function as an antiapoptotic protein [96]. However, it is also believed that c-
FLIPL may also function as a pro-apoptotic protein [48], depending on its isoform and 
expression levels [48,96]. Indeed, it is known that high [19] expression of c-FLIPL blocks 
caspase-8 activation [27,96] while physiological levels of c-FLIPL enhance oligomerization 
and autoproteolytic processing of caspase-8 [27,96]. c-FLIPS has been implicated to 
function in antiapoptotic signaling as well as in increased cell death [48]. Interestingly, c-
FLIPS has been shown to promote necroptosis in response to Toll-like receptor 3 stimulation 
and depletion of IAP proteins [68] by increasing the formation of a cytosolic complex 
containing RIP1, FADD, and caspase-8 [1,68]. Therefore, the finding that the absence of c-
FLIP is an indicator of poor prognosis in PDAC may be due to concept that c-FLIPL can 
function both as an antiapoptotic and proapoptotic factor, depending on the tumor 
environment. The absence of c-FLIP in PDAC as an independent indicator of short overall 
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survival implies that c-FLIP has prognostic value. Moreover, further research into the 
prognostic relevance of c-FLIP in PDAC is required to validate the impact of this protein as 
a prognostic biomarker for this devastating disease. Increased c-FLIP expression is a 
frequent event in stomach carcinoma [81,97], and as McCourt et al. [91] suggested, stomach 
carcinoma cells in vivo may require c-FLIP expression to evade apoptosis and its expression 
is associated with tumor cell proliferation in this cancer [98]. Additionally, c-FLIP 
expression and its relationship with clinicopathologic features of melanoma have been 
actively explored [99]. c-FLIP was found to have an important role in the aggressiveness of 
malignant melanoma and is a useful prognostic marker for patients with this disease [99].
c-FLIP as a mediator of anticancer therapy resistance
Increased expression of c-FLIP in various tumor types is associated with the 
chemotherapeutic resistance and silencing of c-FLIP restores the proapoptotic signaling 
cascades efficiently to enhance chemosensitivity [1,12,46,61]. The association between 
expression of c-FLIP variants and poor prognosis relates to the fact that c-FLIP confers 
resistance to a number of anticancer agents [6,48,99–102] including sorafenib [103], the 
inhibitor of RAF-1 and class II receptor tyrosine kinase. c-FLIP triggers TRAIL resistance 
due to its increased expression level in various human tumors as well as in cancer stem cells 
(CSCs) from these tumors [104]. Furthermore, silencing c-FLIP expression or using c-FLIP 
inhibitors sensitizes tumor cells and CSCs to TRAIL and drugs like Taxol, doxorubicin, 
cisplatin, gemcitabine, etc. [46,100,104–106]. CSCs are also resistant to chemotherapy and 
radiotherapy and play a significant role in cancer recurrence [100]. Expression levels of c-
FLIP isoforms were significantly higher in glioblastoma cancer stem cells (GSCs) than the 
entire GBM tumor cell population, and c-FLIP silencing in GSCs enhanced TRAIL and 
temozolomide (TMZ)-induced apoptosis [107]. It is known that breast cancer stem cells 
(BCSCs) mediate tumor recurrence and drive tumor metastasis [105,108]. Piggott et al. 
[108] reported a therapeutic approach to selectively eliminate BCSCs. They found that c-
FLIP is upregulated in BCSCs from various breast cancer subtypes and that silencing of c-
FLIP by its siRNA partially sensitizes these cells to the anticancer agent TRAIL. 
Significantly, their data demonstrated that BCSCs are sensitive to derepression of the 
proapoptotic pathway by TRAIL due to c-FLIP silencing, which results in an 80% reduction 
in primary tumors, a 98% reduction in tumor metastases, and the loss of BCSC self-renewal.
Overall, c-FLIP can serve as a biomarker for detecting CSCs that are refractory to cell death, 
and inhibition of c-FLIP by pharmacological agents or genetic approaches may be a rational 
therapeutic strategy to increase the efficacy of anti-cancer agents and eliminate the 
apoptosis-resistant CSCs. Phenotypic plasticity is a new paradigm for understanding the 
origin of CSCs and the genesis of interconversion between differentiated cells and CSCs, 
which acquire self-renewal, proliferation, and resistance to therapy [109,110]. Recently, 
Thakur and Ray [111] identified NF-κB as a regulator of dedifferentiation, which increases 
both TNF-α and PIK3CA expression only in the enriched side-population (SP) containing 
CSCs, but not in the nonside-population in platinum-resistant ovarian cancer cells treated 
with cisplatin. Activation of PI3K/AKT signaling pathway drives SPs into an 
undifferentiated state, through increased c-FLIP, P21, and P27 expression [111]. 
Interestingly, Piggott et al. [112] recently identified a novel mechanism of acquired 
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vulnerability to an extrinsic apoptosis stimulus in breast cancer primary cultures and BCSCs 
with acquired resistance to tamoxifen (TAMR) or Faslodex (fulvestrant), which has both 
therapeutic and prognostic potential for breast cancer therapy. In parallel with developing an 
endocrine resistance phenotype, these cells acquired TRAIL sensitivity, which correlated 
with decreased expression of intracellular levels of c-FLIP and an increase in JNK-mediated 
phosphorylation of the E3-ligase ITCH, which degrades c-FLIP. Furthermore, while the 
apoptosis inducing agent lapatinib has clinical efficacy in treating trastuzumab-refractory 
HER2-positive breast cancers, significant proportions of patients develop acquired resistance 
to the drug and develop progressive disease. Eustace et al. [113] demonstrated that the 
development of acquired resistance to lapatinib resulted in triggering TRAIL sensitivity. 
Mechanistically, increased sensitivity to TRAIL in these cells was related to decreased 
phosphorylation of AKT, elevated level of FOX03a and reduced expression of c-FLIP [113]. 
c-FLIPL and c-FLIPS display several roles in various cellular signaling pathways, and 
activate and/or upregulate several cytoprotective and pro-survival signaling proteins that 
include Akt, ERK, and Wnt (Figure 4). Strategies to develop new cancer therapeutics that 
improve the efficacy and decrease the toxicity of chemotherapeutic agents by targeting 
specific c-FLIP isoforms is very attractive [48]. The association between c-FLIP expression 
and poor prognosis in tumors may be because c-FLIP confers resistance to several 
anticancer agents [46,100,104,106]. We have reported that increased expression of c-FLIPL 
or c-FLIPS triggers resistance to Taxol by interacting with caspases-8 and -10 and silencing 
c-FLIP isoforms increases Taxol-induced apoptosis in malignant cells [6]. In colorectal 
cancer (CRC), high c-FLIP expression triggered resistance to #CRC standard-of-care 
chemotherapeutic agents, 5-fluorourcil-and oxaliplatin-triggered apoptosis both in vitro and 
in vivo [114]. Moreover, siRNA mediated silencing of c-FLIP isoforms (particularly c-
FLIPL) to significantly increase cell death by these drugs. Similarly, cisplatin in NSCLC 
models, Taxol in leukemia [6], anticancer drugs in renal cancer cells [106] and ionizing 
radiation in NSCLC [114] trigger more apoptosis when c-FLIP was silenced or inhibited by 
pharmacological inhibitors [1,46,85,101,114]. Interestingly, high expression of cytoplasmic 
c-FLIP is indicative of poor prognosis [75]. Recent data also show that inhibition of the 
bromodomain and extra terminal domain (BET) family inhibitors effectively inhibit c-FLIP 
expression and sensitize KRAS-mutated NSCLC cells to pro-apoptotic agents TRAIL and 
cisplatin [115].
c-FLIP and the tumor immune microenvironment
c-FLIP effects on immune effector cells is a potential reason for the correlation between c-
FLIP expression and poor prognosis in tumors with high c-FLIP expression. c-FLIP can 
prevent cell death induced by immune effector cells [63]. In fact, cytotoxic T lymphocytes 
(CTLs) and natural killer cells express Fas ligand (FasL) and TRAIL, but may exert immune 
resistance in tumors with high c-FLIP expression. Overexpression of c-FLIP has been shown 
to allow establishment of tumors in immune-competent mice by blocking Fas-dependent cell 
death triggered by CTLs on their target tumor cells [62]. c-FLIP is also important in the 
survival of monocytic myeloid-derived suppressor cells (MDSCs) through its ability to 
inhibit death receptor mediated extrinsic apoptosis [12,62,116]. These MDSCs are 
immunosuppressive cells that are recruited to tumors [117] and MDSC numbers may be a 
marker for poor prognosis in cancer patients [118,119]. Zhao et al. [120] have shown that 
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signaling of TNFR-2, but not TNFR-1, promoted MDSC survival through upregulation of c-
FLIP. These results demonstrate that TNFR-2 signaling promotes MDSC survival and 
accumulation through c-FLIP overexpression and helps tumor cells evade the immune 
system [120]. Furthermore, c-FLIP is important for FoxP3+ regulatory T cells (Tregs) 
survival and maintaining local immunosuppressive environments [64]. Particularly 
significant is that c-FLIP knockout in dendritic cells enhanced production of TNF-α, IL2, or 
granulocyte-macrophage colony-stimulating factor (GM-CSF), in response to stimulation of 
TLR4, TLR2, and dectin-1 and increased T cell activation [121]. Therefore, c-FLIP [64] has 
a functional role in immunosuppression.
c-FLIP in Alzheimer’s disease (AD)
Abnormal c-FLIP protein expression has been identified in several diseases including 
multiple sclerosis (MS), Alzheimer’s disease (AD), diabetes mellitus, rheumatoid arthritis 
(RA) and various cancers [30]. Fossati et al. [122] have fund that the TRAIL receptors DR4 
and DR5 specifically mediate oligomeric amyloid-β (Aβ) induction of apoptosis in human 
microvascular cerebral endothelial cells through caspases-8 and -9 activation. Direct binding 
assays using receptor chimeras have confirmed the specific interaction of oligomeric Aβ 
with DR4 and DR5. DR4 and DR5 upregulation and colocalization with Aβ at the cell 
membrane suggests their involvement as initiators of the apoptotic cascade [122]. Aβ 
induced c-FLIP downregulation and the caspase-8-triggered mitochondrial pathway of 
apoptosis through engagement of cleaved Bid. Conversely, apoptosis protection achieved 
through siRNA silencing of DR4 and DR5 highlighted their active role downstream 
apoptotic pathways unveiling new targets in (i.e., c-FLIP, DR4, and DR5) for therapeutic 
intervention for AD. Chemicals and miRNAs known to upregulate [77] c-FLIP may be used 
to relieve depression and anxiety among AD patients. The antidepressant fluoxetine 
upregulates expression of c-FLIP through activating the c-FLIP promoter region spanning 
nucleotides −414 to −133, including the CREB and SP1 sites, and inhibits LPS-induced 
apoptosis in hippocampus-derived neural stem cells (NSCs) [123,124]. Moreover, fluoxetine 
treatment significantly inhibited the induction of proinflammatory factor IL-1β, IL-6, and 
TNF-α in the culture medium of LPS-treated NSCs. Therefore, the activation of c-FLIP by 
fluoxetine indicates its role in neuroprotection. Recent results show that fluoxetine could 
activate the Wnt/β-catenin signaling pathway and reduce amyloidosis in AD brain tissue 
[125]. Interestingly, Wnt/β-catenin is activated by c-FLIP [124]. Therefore, c-FLIP either 
directly or indirectly may be involved in initiating and maintaining AD. Accumulation of β-
amyloid and hyperphosphorylated tau protein in AD probably triggers the neurofibrillary 
tangles and plaques in this disease [123]. At the present, there is no histologic marker for 
AD and recent evidence suggests that the hyperphosphorylation of tau protein in neurons 
may be [9,36] critical in AD. Previously, miR-512 has been shown to prevent c-FLIP 
expression and enhance Taxol triggered apoptosis in hepatocellular carcinoma cells [125]. 
Corroborating these results, miR-512 significantly is reduced in AD brain sections with high 
level of hyperphosphorylated tau protein. Interestingly, immunohistochemistry documented 
that c-FLIP and MCL1, the 2 targets of miRNA-512, were significantly upregulated in AD 
brain, were colocalized with the abnormal tau protein, and no apoptosis was noted in these 
areas [12]. Therefore, these results suggest that increased expression of c-FLIP and MCL1 
may change the balance between apoptosis and anti-apoptotis events in neurons. Similarly, 
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using neuronal cell cultures, Nuovo et al. [11] suggested that molecular changes including 
accumulation of MCL1 and c-FLIP in the affected neurons in AD prevent cell death and 
accumulate hyperphosphorylated tau and β-amyloid. There is no authentic histologic marker 
for AD and the above data underscore the significance of MCL1 and c-FLIP as biomarkers 
for this disease and may offer clues to its etiology. Strategies to upregulate these proteins in 
Alzheimer’s disease may help identify agents to prevent or inhibit the progress of this severe 
the disease.
c-FLIP as a biomarker of COPD
Cigarette smoking (CS) is a critical risk factor for COPD [125]. Pouwels et al. [126] found 
the c-FLIP gene, CFLAR, is has a relationship with CS-triggered release of damage-
associated molecular patterns (DAMP) in airway epithelial cells. Recently, Faiz et al. [13] 
studied the effect of CS on CFLAR expression levels in bronchial biopsies from smokers 
and non-smokers and isoform-expression of CFLAR transcripts in air-liquid interface-
differentiated bronchial epithelial cells (BECs). These investigators concluded that CS 
exposure significantly decreased CFLAR expression in BECs. Furthermore, there was a shift 
in relative levels of the isoform c-FLIPS and c-FLIPL isoform transcripts in bronchial 
biopsies of smokers compared to non-smokers, correlated with cell death. The proof of 
concept came from in vitro downregulation of CFLAR by siRNA, which showed increased 
apoptosis, necrosis, and DAMP release as observed in CS. As this study concluded, CS 
exposure downregulates CFLAR expression. Moreover, decrease in c- FLIP might increase 
susceptibility of BECs to immunogenic cell death. Therefore, c-FLIP serves as a molecular 
biomarker for DAMPs and COPD [127–129].
Conclusion
Deregulation of c-FLIP plays crucial roles in several diseases including cancer, AD, and 
COPD. c-FLIP is a master apoptosis regulator frequently overexpressed in various 
malignancies and its upregulation is often correlated with a poor prognosis. It is well 
documented that c-FLIP isoforms induce resistance to death receptor ligands such as 
TRAIL, chemotherapeutic agents, and various cell death mechanisms in malignant cells, and 
is a rational target for modulating therapy-resistant human malignances Transitory 
pharmacological inhibition of c-FLIP is adequate to sensitize cancer cells to 
chemotherapeutics. Agents that indirectly target c-FLIP, such as the drug entinostat (also 
known as MS-275 or SNDX-275) used for aromatase inhibitor-resistant breast cancer, have a 
therapeutic window and usefulness which suggests more specific c-FLIP-targeted agents 
will also be tolerated and effective. Moreover, in addition to high expression of c-FLIP in 
various cancers, specific mutations may serve as biomarkers and provide c-FLIP 
“dependency” in certain cancers. For example, an important function of c-FLIPL is 
activation of the NLRP3 and AIM2 inflammasomes and NSCLC cells with NLRP3 
mutations are hypersensitive to cell death due to the loss of c-FLIP expression. Therefore, 
this hypersensitivity serves as a potential biomarker to identify a subgroup of patients who 
display enhanced vulnerability to c-FLIP-targeted therapies. Significantly, c-FLIP plays 
major roles in promoting the survival of immunosuppressive tumor promoting immune cells 
and function in inflammation, Alzheimer’s disease and COPD. Thus, the foregoing 
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discussion and these conclusions show that c-FLIP can serve as a versatile biomarker for 
cancer prognosis, a diagnostic marker for several diseases, and as a therapeutic window for 
direct targeting.
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c-FLIP variants as anti-apoptotic proteins control apoptosis and pathways. Binding of 
TRAIL with its receptors DR4 and DR5 or interaction of Fas ligand (CD95L) to Fas 
receptor (CD95) triggers the death receptor (extrinsic) and subsequently mitochondrial 
apoptosis signaling (intrinsic) pathways through FADD-dependent autocatalytic activation of 
caspases-8 and -10 and Bid cleavage to truncated Bid. c-FLIPL and c-FLIPS isoforms 
suppress caspase-8 and -10 activation, therefore preventing the downstream apoptosis 
cascade (Modified from Safa [1]).
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Death receptor and mitochondrial apoptosis signaling pathways and blocking TNFR1-
mediated apoptosis by c-FLIP. TNF-α binds to its receptor TNFR1, which results in 
formation of Complex I containing TNFR1, TRADD, TRAF2 and RIP. Complex I mediates 
the NF-κB activation pathway and occurs through the MEKK3-IKK-IκB-NF-κB cascade, 
leading to the expression of c-FLIPL and c-FLIPS isoforms. TNF-α treatment through 
Complex I also activates JNK and ERK through the MAPK signaling pathway. The 
ubiquitin-E3-ligase ITCH promotes the ubiquitylation and proteasomal degradation of c-
FLIP isoforms. As a result of degradation, levels of c-FLIP protein isoforms decrease. 
Complex II consists of RIP, TRADD, FADD, and procaspase-8. Caspase-8 is autoactivated 
and activates caspases-3 and -7, there by triggering apoptosis. Caspase-8 induces cleavage of 
the proapoptotic protein Bid to truncated Bid (tBid) which activates the mitochondrial 
apoptosis pathway that involves the release of cytochrome c and Smac/DIABLO from the 
mitochondria. Cytochrome c binds to Apaf1 to activate caspase-9-mediated executor 
caspases (Modified and updated from Safa).
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Structures of c-FLIP variants and their cleavage products. c-FLIP isoforms (c-FLIPL, c-
FLIPS, and c-FLIPR) have two death effector domains (DED1 and DED2) at their N termini 
which are required for DISC recruitment. In addition to two DEDs, c-FLIPL has a significant 
similarity to caspase-8 and has large (p20) and small (p12) caspase-like domains, which are 
catalytically inactive. c-FLIPS and c-FLIPR consist of two DEDs and a small C terminus. c-
FLIPL can be cleaved by caspase-8 generating the N-terminal fragments p43-FLIP or p22-
FLIP. The phosphorylation (P) and ubiquitination (U) sites are indicated [1]. The p20/p12 
regions interact with TRAF2 and RIP1, respectively, and Ku70 binds to DED2 (Modified 
and updated from Safa [1]).
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Roles of c-FLIPL on cell survival and cell proliferation. As discussed in the text, in addition 
to its functional role in inhibiting apoptosis by binding to procaspases-8 and -10 and 
inhibiting their activation, c-FLIPL activates cell survival and cell proliferation by 
controlling MAPK, AKT, mTOR, Wnt/β-catenin, NF-κB, and STAT3 signaling pathways.
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